Industry News

Join WhatsApp Channel 

GPAT caoching

  • Novo Nordisk, a world leader in insulin and diabetes care,  has launched Saxenda (liraglutide 3 mg), the first glucagon-like peptide-1 (GLP-1) receptor agonist the United States.  Saxenda is a drug used to treat obesity.  Saxenda has approved in the US, EU and Canada.

  • Launch Avycaz by Actavis in US markets to treat cIAI and complicated urinary tract infections
    28 April 2015
    Launch Avycaz by Actavis in US markets to treat cIAI and complicated urinary tract infections

    In the United States, Actavis plc, global pharmaceutical company, has launched Avycaz (ceftazidime-avibactam) to treat adult patients with complicated intra-abdominal infections (cIAI) (in combination with metronidazole) and complicated urinary tract infections (cUTI) including pyelonephritis caused by designated susceptible bacteria, including certain Enterobacteriaceae and Pseudomonas aeruginosa. Avycaz should be reserved for use in patients who have limited or no alternative treatment options.

  • Mylan Pharmaceuticals Private Limited, a subsidiary of Mylan N.V.,  has launched generic sofosbuvir 400 mg tablets under the brand name MyHep in India. The product is used for the treatment of chronic hepatitis C,which is a long-lasting infection with the hepatitis C virus. Chronic hepatitis C is a blood-borne infectious disease that affects more than 100 million people in the developing world, including approximately 12 million people in India.

  • Mauna Kea Technologies, inventor of Cellvizio, the multidisciplinary confocal laser endomicroscopy platform, has received regulatory approval from COFEPRIS (Comisión Federal Para la Protección contra Riesgos Sanitarios), the Mexican health authority, for the commercialization of Cellvizio.. Mauna Kea Technologies is now able to implement its marketing strategy with its partner, Endomédica, a company specialized in the fields of interventional endoscopy, gastroenterology, urology and surgery since 1986.

  • Merck, a leading company for innovative and top-quality high-tech products in healthcare, life science and performance materials, in collaboration with Maharashtra University of Health Sciences and Directorate of Medical Education & Research is introducing European Accredited Clinical Diabetes management for more than 5000 medical students in 18 medical colleges of Maharashtra University as part of Merck Capacity Advancement Program (CAP) in Asia.

  • Lupin introduce Zaxine in Canada for liver disease treatment
    23 April 2015
    Lupin introduce Zaxine in Canada for liver disease treatment

    Pharma Major Lupin’s Canadian subsidiary, Lupin Pharma Canada has launched its first Brand product Zaxine under a strategic licensing agreement with the North Carolina based GI specialty company Salix Pharmaceuticals Inc. The agreement grants Lupin exclusive rights to promote, distribute and market Zaxine in the Canada.

  • A team of three engineering students from Rice University, Houston, United States, created the device to ease the pain of an injection. A new drug injector called "Comfortably Numb" is a cooling device. It numbs the skin prior to getting a shot.  It works like an ice pack, which produces a rapid chemical reaction that cools and numbs patients' skin in seconds. The device consists of a small 3D-printed cylinder with a metal plate at one end. It contain ammonium nitrate and water in separate compartments.

Subscribe to Industry News